预防癌症血栓形成的运动训练 (EXPECT) 试点试验 (EXPECT)
研究概览
详细说明
血液凝固系统的激活是与静脉血栓栓塞 (VTE) 过早死亡相关的癌症的常见表现。(1-5) 接受淋巴瘤或肺癌、卵巢癌、胃癌、膀胱癌和胰腺癌等癌症化疗的门诊癌症患者在 1 年时的 VTE 绝对发生率为 12.6%,与年龄-性别匹配的对照组相比,近 50% 的 VTE 事件发生在治疗的前 3 个月内。(6) 此外,与未经历过 VTE 的癌症患者相比,发生 VTE 的癌症患者的死亡风险高 2.5 倍。(3) 目前尚无抵消 VTE 风险的疗法,例如低分子肝素或维生素 K 拮抗剂美国临床肿瘤学会指南推荐继发于缺乏可靠的临床试验数据、潜在出血以及需要监测和剂量调整。 (7) 因此,迫切需要在化疗期间预防 VTE 而不增加进一步毒性的替代策略。
研究人员假设有氧运动训练是一种治疗策略,可以减轻接受化疗的门诊癌症患者的 VTE 风险。 中等强度的有氧运动训练对凝血因子有有利影响,可降低健康人群发生 VTE 的风险。 (8-11) 迄今为止,尚无研究确定运动训练是否对与 VTE 风险相关的凝血因子产生有利影响。 此外,缺乏关于运动训练对化疗期间门诊癌症患者功能表现和患者报告结果的影响的数据。 该拨款申请的重点是确定有氧运动训练是否可以作为一种潜在的方式来预防化疗期间门诊淋巴瘤和癌症患者的静脉血栓栓塞症。
为此,研究人员提出了预防癌症血栓形成的运动训练 (EXPECT) 试点试验,这是一项双臂随机对照试验 (RCT),比较有氧运动训练(每周 3 次有监督的跑步机训练,不连续几天,持续 12 周,强度适中强度(基线 VO2max 的 50-70%),与 54 名受试者(27 名/组)中的对照相比。 在门诊接受化疗的高风险 VTE 恶性肿瘤患者将成为招募的重点。 (2, 6, 12) 主要终点将是凝血酶生成的变化,(13) 以及癌症中其他已确定的 VTE 风险标志物。(14, 15) 我们还将评估运动训练与 Xa 因子生成之间的关系,Xa 因子是血栓形成的关键调节剂和 VTE 预防的新治疗靶点。 (16, 17)
设计和程序:研究临床研究协调员将通过对计划在佛蒙特州癌症中心开始化疗的候选人的病历审查来确定和筛选潜在参与者的资格。 获得书面同意后,所有参与者将完成以下基线评估:(1) 空腹抽血和 (2) 心肺运动试验 (CPET)。 在 12 周干预结束时将重复抽血和 CPET 基线评估。
分组(随机化):在开始化疗之前,参与者将根据个人情况随机分配到两个研究组之一。 在剩下的研究中,随机分配的参与者将留在同一组中(即没有交叉)。 随机化将按癌症类型分层,以确保组间类型的平衡。
运动干预:
所有参与者都同意参加运动测试、运动记录、抽血以及干预前后的调查。 根据随机化,干预将包括:
第 1 组 - 所有 AT 组的目标是每周 3 次监督锻炼,强度为个人确定的 VO2max 的 50%-70%,每次锻炼 30-45 分钟,持续 12 周。 有氧训练干预将密切模仿心脏康复中采用的基于运动的标准指南。 所有干预课程都将在有监督的环境中进行,并由美国运动医学会认证的运动生理学家进行一对一的监督。 有氧运动训练将根据 ACSM 指导原则进行规定,目的是提高 VO2max。 选择步行是因为它是癌症患者首选的运动训练方式。 (51) 第 2 组 - 控制组:为期 12 周的计划将包括每月电话联系以与患者核对并查看他们当月的锻炼日志条目,以捕获在干预设置之外进行的身体活动。
研究终点:
VTE 风险标志物:研究人员将测量以下 VTE 风险标志物:凝血酶、FXa、F 1+2、TAT、D-二聚体、vWF、可溶性 P-选择素和 C-反应蛋白。 样本将在诊所进行处理,注意与凝血激活相关的问题,血浆和血清将在我们的实验室中储存在 -80 摄氏度。
功能能力: VO2peak:为确定 VO2peak,将由 ACSM 认证的运动生理学家执行带有 12 导联心电图监测 (Mortara) 的增量跑步机测试(改进的 Balke 协议)。 代谢测量系统 (Sensormedics Vmax 29c) 将连续分析呼出的气体。 身体机能还将包括主观(即 SF-36)评估以及如前所述的 6 分钟步行距离测试。 (55) 疲劳:疲劳症状量表 (FSI) 已在多个癌症患者群体中进行了测试,并将用于评估疲劳 (56) 焦虑和抑郁将使用医疗结果研究简式健康调查 (SF-36) 进行评估。 这是一种广泛使用和验证的工具,用于评估一般功能和健康相关的生活质量。 (58) SF-36 是一个 36 项的工具,包含八个单独的量表,测量以下领域:身体机能、身体角色、身体疼痛、社会功能、心理健康、活力、角色情绪和一般健康感知。
运动经验:个人的运动经验预示着参与运动干预。
锻炼自我效能:自我效能是指一个人相信他/她可以成功完成给定的活动。 (59) 将通过评估研究合格率、接受率和总体应计率来评估依从性。
安全性将根据运动相关评估期间不良事件的类型和发生率进行评估。
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Vermont
-
Burlington、Vermont、美国、05401
- Fletcher Allen Healthcare
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
纳入标准:
- 淋巴瘤或癌症的诊断
- 开始化疗方案
- 患者自我报告步行 10 分钟的能力而不会中断或疼痛
- 年龄 >18 且 <80
- 愿意参加 Tilley Drive South Burlington 的肿瘤康复计划
排除标准:
- 进入前有 DVT 或 PE 的存在或病史
- 抗血栓治疗包括华法林、达比加群、低分子肝素或普通肝素,它们会改变止血因子的水平(在第一次研究抽血前 48 小时关闭 Lovenox)
- 改变步行锻炼能力的医疗状况
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:第 1 组 - 有监督的有氧运动训练
该小组将参加 3 次监督锻炼课程/周,强度为个人确定的 VO2max 的 50%-70%,每次锻炼 30-45 分钟,持续 12 周。
有氧训练干预将密切模仿心脏康复中采用的基于运动的标准指南。
所有干预课程都将在有监督的环境中进行,并由美国运动医学会认证的运动生理学家进行一对一的监督。
有氧运动训练将根据 ACSM 指导原则进行规定,目的是提高 VO2max。
选择步行是因为它是癌症患者首选的运动训练方式。
|
|
|
无干预:第 2 组
这个为期 12 周的计划将包括每月电话联系,以与患者核对并查看他们当月的锻炼日志条目,以捕捉在干预环境之外进行的身体活动。
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
凝血酶生成
大体时间:12周
|
主要终点将是凝血酶的产生,这是癌症中 VTE 风险的标志。
|
12周
|
合作者和调查者
调查人员
- 首席研究员:Susan G Lakoski, MD、University of Vermont
出版物和有用的链接
一般刊物
- ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. doi: 10.1164/ajrccm.166.1.at1102. No abstract available. Erratum In: Am J Respir Crit Care Med. 2016 May 15;193(10):1185.
- Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83.
- Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092.
- Hann DM, Jacobsen PB, Azzarello LM, Martin SC, Curran SL, Fields KK, Greenberg H, Lyman G. Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual Life Res. 1998 May;7(4):301-10. doi: 10.1023/a:1024929829627.
- Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998 Mar 23;158(6):585-93. doi: 10.1001/archinte.158.6.585.
- Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A, Schneider CM, von Gruenigen VE, Schwartz AL; American College of Sports Medicine. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010 Jul;42(7):1409-26. doi: 10.1249/MSS.0b013e3181e0c112. Erratum In: Med Sci Sports Exerc. 2011 Jan;43(1):195.
- Jones LW, Courneya KS, Mackey JR, Muss HB, Pituskin EN, Scott JM, Hornsby WE, Coan AD, Herndon JE 2nd, Douglas PS, Haykowsky M. Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol. 2012 Jul 10;30(20):2530-7. doi: 10.1200/JCO.2011.39.9014. Epub 2012 May 21.
- Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008 May 15;111(10):4902-7. doi: 10.1182/blood-2007-10-116327. Epub 2008 Jan 23.
- Marcus BH, Selby VC, Niaura RS, Rossi JS. Self-efficacy and the stages of exercise behavior change. Res Q Exerc Sport. 1992 Mar;63(1):60-6. doi: 10.1080/02701367.1992.10607557.
- Knols R, Aaronson NK, Uebelhart D, Fransen J, Aufdemkampe G. Physical exercise in cancer patients during and after medical treatment: a systematic review of randomized and controlled clinical trials. J Clin Oncol. 2005 Jun 1;23(16):3830-42. doi: 10.1200/JCO.2005.02.148.
- Jones LW, Eves ND, Peterson BL, Garst J, Crawford J, West MJ, Mabe S, Harpole D, Kraus WE, Douglas PS. Safety and feasibility of aerobic training on cardiopulmonary function and quality of life in postsurgical nonsmall cell lung cancer patients: a pilot study. Cancer. 2008 Dec 15;113(12):3430-9. doi: 10.1002/cncr.23967.
- Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000 Mar 27;160(6):809-15. doi: 10.1001/archinte.160.6.809.
- Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW; American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007 Dec 1;25(34):5490-505. doi: 10.1200/JCO.2007.14.1283. Epub 2007 Oct 29.
- Brummel-Ziedins K, Undas A, Orfeo T, Gissel M, Butenas S, Zmudka K, Mann KG. Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition. J Thromb Haemost. 2008 Jan;6(1):104-10. doi: 10.1111/j.1538-7836.2007.02799.x. Epub 2007 Oct 15.
- Wang T, Nelson RA, Bogardus A, Grannis FW Jr. Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer. 2010 Mar 15;116(6):1518-25. doi: 10.1002/cncr.24871.
- Galvao DA, Newton RU. Review of exercise intervention studies in cancer patients. J Clin Oncol. 2005 Feb 1;23(4):899-909. doi: 10.1200/JCO.2005.06.085.
- Jones LW, Eves ND, Haykowsky M, Joy AA, Douglas PS. Cardiorespiratory exercise testing in clinical oncology research: systematic review and practice recommendations. Lancet Oncol. 2008 Aug;9(8):757-65. doi: 10.1016/S1470-2045(08)70195-5.
- Wang JS, Li YS, Chen JC, Chen YW. Effects of exercise training and deconditioning on platelet aggregation induced by alternating shear stress in men. Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):454-60. doi: 10.1161/01.ATV.0000151987.04607.24. Epub 2004 Nov 29.
- Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007 Mar;5(3):632-4. doi: 10.1111/j.1538-7836.2007.02374.x. No abstract available.
- Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006 Feb 27;166(4):458-64. doi: 10.1001/archinte.166.4.458.
- Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm AA. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999 Sep;78(5):285-91. doi: 10.1097/00005792-199909000-00001.
- Flinterman LE, van Hylckama Vlieg A, Cannegieter SC, Rosendaal FR. Long-term survival in a large cohort of patients with venous thrombosis: incidence and predictors. PLoS Med. 2012 Jan;9(1):e1001155. doi: 10.1371/journal.pmed.1001155. Epub 2012 Jan 10.
- Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000 Dec 21;343(25):1846-50. doi: 10.1056/NEJM200012213432504.
- Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013 Feb 1;119(3):648-55. doi: 10.1002/cncr.27772. Epub 2012 Aug 14.
- Wang JS. Exercise prescription and thrombogenesis. J Biomed Sci. 2006 Nov;13(6):753-61. doi: 10.1007/s11373-006-9105-7. Epub 2006 Aug 24.
- Lee KW, Lip GY. Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch Intern Med. 2003 Oct 27;163(19):2368-92. doi: 10.1001/archinte.163.19.2368.
- van Stralen KJ, Le Cessie S, Rosendaal FR, Doggen CJ. Regular sports activities decrease the risk of venous thrombosis. J Thromb Haemost. 2007 Nov;5(11):2186-92. doi: 10.1111/j.1538-7836.2007.02732.x. Epub 2007 Aug 14.
- Rauramaa R, Li G, Vaisanen SB. Dose-response and coagulation and hemostatic factors. Med Sci Sports Exerc. 2001 Jun;33(6 Suppl):S516-20; discussion S528-9. doi: 10.1097/00005768-200106001-00022.
- Ay C, Dunkler D, Simanek R, Thaler J, Koder S, Marosi C, Zielinski C, Pabinger I. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2011 May 20;29(15):2099-103. doi: 10.1200/JCO.2010.32.8294. Epub 2011 Apr 4.
- Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach J, Quehenberger P, Wagner O, Zielinski C, Pabinger I. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2009 Sep 1;27(25):4124-9. doi: 10.1200/JCO.2008.21.7752. Epub 2009 Jul 27.
- Connolly GC, Khorana AA. Risk stratification for cancer-associated venous thromboembolism. Best Pract Res Clin Haematol. 2009 Mar;22(1):35-47. doi: 10.1016/j.beha.2008.12.006.
- Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost. 2007 Jul;5 Suppl 1:60-4. doi: 10.1111/j.1538-7836.2007.02473.x.
- Gomez-Outes A, Terleira-Fernandez AI, Suarez-Gea ML, Vargas-Castrillon E. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ. 2012 Jun 14;344:e3675. doi: 10.1136/bmj.e3675.
- Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012 Feb 16;366(7):601-9. doi: 10.1056/NEJMoa1108898.
- Akl EA, Vasireddi SR, Gunukula S, Yosuico VE, Barba M, Terrenato I, Sperati F, Schunemann H. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006466. doi: 10.1002/14651858.CD006466.pub2.
- Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e195S-e226S. doi: 10.1378/chest.11-2296.
- Lockard MM, Gopinathannair R, Paton CM, Phares DA, Hagberg JM. Exercise training-induced changes in coagulation factors in older adults. Med Sci Sports Exerc. 2007 Apr;39(4):587-92. doi: 10.1249/mss.0b013e31802eff4b.
- Wannamethee SG, Lowe GD, Whincup PH, Rumley A, Walker M, Lennon L. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation. 2002 Apr 16;105(15):1785-90. doi: 10.1161/hc1502.107117.
- Lindqvist PG, Epstein E, Olsson H. The relationship between lifestyle factors and venous thromboembolism among women: a report from the MISS study. Br J Haematol. 2009 Jan;144(2):234-40. doi: 10.1111/j.1365-2141.2008.07460.x. Epub 2008 Nov 19.
- Patnaik SK, Kannisto E, Mallick R, Yendamuri S. Overexpression of the lung cancer-prognostic miR-146b microRNAs has a minimal and negative effect on the malignant phenotype of A549 lung cancer cells. PLoS One. 2011;6(7):e22379. doi: 10.1371/journal.pone.0022379. Epub 2011 Jul 18.
- Patnaik JL, Byers T, Diguiseppi C, Denberg TD, Dabelea D. The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst. 2011 Jul 20;103(14):1101-11. doi: 10.1093/jnci/djr188. Epub 2011 Jun 30.
- Wei S, Pan Z, Siegal GP, Winokur TS, Carroll AJ, Jhala D. Complex analysis of a recurrent pleomorphic hyalinizing angiectatic tumor of soft parts. Hum Pathol. 2012 Jan;43(1):121-6. doi: 10.1016/j.humpath.2011.02.023. Epub 2011 Jul 5.
- Evenson KR, Stevens J, Thomas R, Cai J. Effect of cardiorespiratory fitness on mortality among hypertensive and normotensive women and men. Epidemiology. 2004 Sep;15(5):565-72. doi: 10.1097/01.ede.0000129527.53181.c8.
- Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol. 2007 May;62(2):126-36. doi: 10.1016/j.critrevonc.2007.01.001. Epub 2007 Feb 12.
- Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 2002 Nov-Dec;4(6):465-73. doi: 10.1038/sj.neo.7900263.
- Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res. 2001 Jun 15;102(6):V215-24. doi: 10.1016/s0049-3848(01)00285-7.
- Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest. 2003 Sep;124(3 Suppl):58S-68S. doi: 10.1378/chest.124.3_suppl.58s.
- Butenas S, Mann KG. Blood coagulation. Biochemistry (Mosc). 2002 Jan;67(1):3-12. doi: 10.1023/a:1013985911759.
- Butenas S, van 't Veer C, Mann KG. Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases. J Biol Chem. 1997 Aug 22;272(34):21527-33. doi: 10.1074/jbc.272.34.21527.
- Gissel M, Undas A, Slowik A, Mann KG, Brummel-Ziedins KE. Plasma factor and inhibitor composition contributes to thrombin generation dynamics in patients with acute or previous cerebrovascular events. Thromb Res. 2010 Oct;126(4):262-9. doi: 10.1016/j.thromres.2010.07.002. Epub 2010 Aug 14.
- Brummel-Ziedins K, Vossen CY, Rosendaal FR, Umezaki K, Mann KG. The plasma hemostatic proteome: thrombin generation in healthy individuals. J Thromb Haemost. 2005 Jul;3(7):1472-81. doi: 10.1111/j.1538-7836.2005.01249.x.
- Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood. 2002 Jul 1;100(1):148-52. doi: 10.1182/blood.v100.1.148.
- Baglin T. The measurement and application of thrombin generation. Br J Haematol. 2005 Sep;130(5):653-61. doi: 10.1111/j.1365-2141.2005.05612.x.
- Goldenberg N, Kahn SR, Solymoss S. Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism. J Clin Oncol. 2003 Nov 15;21(22):4194-9. doi: 10.1200/JCO.2003.05.165.
- Brummel-Ziedins KE, Orfeo T, Gissel M, Mann KG, Rosendaal FR. Factor Xa generation by computational modeling: an additional discriminator to thrombin generation evaluation. PLoS One. 2012;7(1):e29178. doi: 10.1371/journal.pone.0029178. Epub 2012 Jan 11.
- Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008 Nov 19;300(19):2277-85. doi: 10.1001/jama.2008.656.
- Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem. 1995 Feb;41(2):264-70.
- Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem. 2002 May 24;277(21):18322-33. doi: 10.1074/jbc.M201173200. Epub 2002 Mar 13.
- Butenas S, Orfeo T, Gissel MT, Brummel KE, Mann KG. The significance of circulating factor IXa in blood. J Biol Chem. 2004 May 28;279(22):22875-82. doi: 10.1074/jbc.M400531200. Epub 2004 Mar 23.
- Ay C, Haselbock J, Laczkovics C, Koder S, Pabinger I. Thrombin generation in patients with a bleeding tendency of unknown origin. Ann Hematol. 2011 Sep;90(9):1099-104. doi: 10.1007/s00277-011-1201-8. Epub 2011 Feb 26.
- Poerwanto S, Stevenson M, de Klerk N. Infant mortality and family welfare: policy implications for Indonesia. J Epidemiol Community Health. 2003 Jul;57(7):493-8. doi: 10.1136/jech.57.7.493.
- Jones LW, Eves ND, Mackey JR, Peddle CJ, Haykowsky M, Joy AA, Courneya KS, Tankel K, Spratlin J, Reiman T. Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer. Lung Cancer. 2007 Feb;55(2):225-32. doi: 10.1016/j.lungcan.2006.10.006. Epub 2006 Nov 17.
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.